Evaxion Biotech (EVAX) said Thursday that new preclinical data showed its experimental acute myeloid leukemia vaccine, EVX-04, was able to kill target cancer cells.
The company said all endogenous retroviral antigens included in the vaccine triggered targeted immune responses in both mouse studies and human cell experiments across a range of immune profiles.
Evaxion added that it is continuing preclinical development of EVX-04 while preparing the regulatory filings needed to begin clinical testing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments